A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2018
Price : $35 *
At a glance
- Drugs HDM SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Circassia
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 18 Apr 2017 Top-line results published in a Circassia Media Release.
- 18 Apr 2017 Primary endpoint has not been met. (Combined score of symptoms and allergy medication)